Although anti-PD-1/PD-L1 and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies are studied extensively in glioma, most are in phase I or phase II clinical research stages (26, 27). Here, CD274 is linked to central nervous system cancer.